Innate Pharma, S.A. - IPHA Net earnings per share for the last four quarters

Innate Pharma S.A. (IPHA) integrates environmental standards and bioethics into the development of anti-tumor antibodies. This price chart confirms the EPS dynamics, which currently stand at 1.20. The business generates revenue through the licensing of innovations, receiving long-term royalties from pharma behemoths. Research stability is supported by streamlined air delivery of biomaterials to global centers, ensuring the precision and continuity of all scientific processes.

Innate Pharma (IPHA) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/15/2026

IPHA (Innate Pharma): analytical breakdowns and indicator data

- current price and projected stock value:

Price Performance Chart Innate Pharma|IPHA - Analyst Consensus Forecast

- issuer market value details:

Market Capitalization Innate Pharma S.A|IPHA - Total Company Value

- book value of equity indicators:

Accounting Value per Share Innate Pharma|IPHA - Company Book Value|Market Cap to Net Assets Ratio innate-pharma.com|IPHA - Cumulative Company Assets

- debt and liquidity data:

- earnings and market multiples details:

IPHA - Net Profit|Expected Net Income Innate Pharma S.A.|IPHA - P/E Multiple|Projected Price to Earnings Ratio Innate Pharma S.A|IPHA - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Innate Pharma, S.A.|IPHA - Operating profit EBITDA|Net earnings per share (EPS TTM) Innate Pharma|IPHA - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months innate-pharma.com|IPHA - Net earnings per share growth this year|Expected net earnings per share growth next year Innate Pharma S.A.

- revenue and sales details:

IPHA - Revenue and Sales Volume|Company Future Sales Innate Pharma SA|IPHA - Price-to-Revenue Ratio|Market Cap to Projected Revenue Innate Pharma S.A

Initial company analysis:IPHA, Innate Pharma, S.A.

Mass-produced product of innate-pharma.com

Analyzing the TTM annual net income per share growth trend, we assess the status of Innate Pharma S.A. (IPHA) as a French oncology biotech. This indicator measures profit dynamics over 12 months, excluding one-time write-offs to identify the actual fundamental margin of safety. The gap between GAAP and adjusted data determines the risk of inflated investor expectations. For the company's academic culture, such transparency confirms the effectiveness of grant programs and the resilience of its scientific mission.

Direct competitors